Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…
Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting
Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Ginger L. Janow¹, Laura Schanberg², Soko Setoguchi³, Elizabeth D. Mellins⁴, Rayfel Schneider⁵, Yukiko Kimura^1,6 and The CARRA Registry Investigators⁷, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁷Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 290 • 2014 ACR/ARHP Annual Meeting
Patterns of Active Joint Involvement in JIA
Simon W.M. Eng¹, Mira Van Veenendaal², Alan M. Rosenberg³, Kiem Oen⁴, Quaid Morris¹ and Rae S.M. Yeung², ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Pediatrics RR149 Rehab Ctr, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: JIA encompasses a set of heterogeneous diseases with chronic joint inflammation. Although the ILAR criteria consider joint counts, they do not reflect specific joint…
Abstract Number: 2294 • 2014 ACR/ARHP Annual Meeting
The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom
Timothy Beukelman¹, Roberto Carrasco², Yukiko Kimura³, Laura Schanberg⁴, Wendy Thomson⁵, Kimme L. Hyrich⁶, For the CARRA Registry Investigators⁷ and For the CAPS Investigators Group⁸, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁴Duke University, Durham, NC, ⁵Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁶Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ⁷CARRA, Durham, NC, ⁸CAPS, Manchester, United Kingdom
Background/Purpose: Systemic JIA (sJIA) treatment has changed dramatically with the introduction of biologic agents, although treatment approaches may differ between countries. We characterized and compared…
Abstract Number: 289 • 2014 ACR/ARHP Annual Meeting
Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab
Gerd Horneff¹, Carol A. Wallace², Pierre Quartier³, Daniel J. Kingsbury⁴, Kirsten Minden⁵, Mareike Bereswill⁶, Vishvas Garg⁷, Hartmut Kupper⁶ and Jasmina Kalabic⁶, ¹Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ²University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ⁴Randall Children's Hospital at Legacy Emanuel, Portland, OR, ⁵Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood and adolescents, and improvement in health-related quality of life and…
Abstract Number: 2301 • 2014 ACR/ARHP Annual Meeting
The New Proposal Classification Criteria for Juvenile Spondyloarthropaties
Ozgur Kasapcopur¹, Metin Sezen¹, Kenan Barut¹ and Cengizhan Acikel², ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ²Department of Bioistatistics, Gulhane Military Medical Academy, Ankara, Turkey
Background/Purpose Juvenile spondyloarthropathies (JSpA) are a group of rheumatologic diseases with a disease onset before 16 years of age and are characterized with enthesitis, lower…
Abstract Number: 273 • 2014 ACR/ARHP Annual Meeting
Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Hermine Brunner¹, Nicola Ruperto², Carol A. Wallace³, Mary Toth⁴, Ivan Foeldvari⁵, John Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Pavla Vavrincova⁹, Daniel J. Kingsbury¹⁰, Katherine Marzan¹¹, Pierre Quartier¹², Kirsten Minden¹³, Elizabeth Chalom¹, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason Dare¹⁶, Mareike Bereswill¹⁷, Hartmut Kupper¹⁷, Jasmina Kalabic¹⁷, Daniel Lovell¹⁸ and Alberto Martini¹⁹, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²PRINTO, Genoa, Italy, ³University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ⁴Akron Children's Hospital, Akron, OH, ⁵Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ⁶University of Utah, Department of Pediatrics, Salt Lake City, UT, ⁷Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NC, ⁹Fakultni nemocnice v Motole, Praha, Czech Republic, ¹⁰Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹³Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, ¹⁹PRINTO-IRCCS, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases of childhood. Adalimumab (ADA) is approved for moderate to severe polyarticular JIA…
Abstract Number: 2286 • 2014 ACR/ARHP Annual Meeting
Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis
Trevor E. Davis^1,2, Mei-Sing Ong³, Diana Milojevic², Jyoti Ramakrishna⁴ and Marc D. Natter⁵, ¹Medicine, Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Pediatrics, Division of Pediatric Rheumatology, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ³Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ⁴Pediatrics, Division of Pediatric Gastroenterology and Nutrition, Floating Hospital for Children at Tufts Medical Center, Boston, MA, ⁵Intelligent Health Labs, Children's Hospital Boston, Boston, MA
Background/Purpose: There are multiple strong associations between gut pathology and rheumatologic diseases. This connection, between primary GI disease and rheumatologic diseases, is manifest in both…
Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers
Rebecca Davies¹, Lianne Kearsley-Fleet¹, Eileen Baildam², Michael W. Beresford³, Helen E. Foster⁴, Taunton R. Southwood⁵, Wendy Thomson⁶, Kimme L. Hyrich⁷, on Behalf Of The BSPAR Etanercept Cohort Study¹ and The Biologics for Children with Rheumatic Diseases (BCRD) study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁵Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ⁶Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…
Abstract Number: 2290 • 2014 ACR/ARHP Annual Meeting
Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis
Sheila T. Angeles-Han¹, Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Erica Myoung⁴, Daneka Stryker⁴, Kelly A. Rouster-Stevens⁵, Larry B. Vogler¹, Christine Kennedy⁶, Sampath Prahalad¹ and Carolyn Drews-Botsch⁷, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes. American Academy of Pediatric guidelines recommend screening every 3 months in children with…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…
Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Sasha Bernatsky³, Ciaran Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ⁴Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁵McGill University Heatlh Center, Montreal, QC, Canada, ⁶médecine sociale et préventive, Université de Montréal, Montréal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…
Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Kamal N. Bharucha¹, Hermine I. Brunner², Nicola Ruperto³, David A. Cabral², Abraham Gedalia², Valeria Gerloni³, Christian Jorgensen³, Athimalaipet Ramanan³, Daniel Lovell², Alberto Martini⁴, James Frane⁵, Chris Wells⁶ and Fabrizio De Benedetti Sr.⁷, ¹Genentech, South San Francisco, CA, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Consultant, Santa Monica, CA, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].